author-photo

Maria Luckevich

Novo Nordisk

4

Papers

3

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial: Hospitalization costs – degludec vs glargine

2021 Journal of Medical Economics
Show All
- Source
- Cite
- Save
Citations (0)
Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)

2019 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (2)
Short-Term Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine 100 Units/mL for Patients with Type 2 Diabetes at High Risk of Hypoglycemia in DEVOTE

2018 Canadian Journal of Diabetes
Show All
- Source
- Cite
- Save
Citations (1)